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Abstract: Many critically ill patients are benefiting from extensive research done in tight glucose control 
(TGC) within the ICU. But moderate to high levels of hyperglycaemia are still tolerated within high 
dependency (HDU) and surgical units. The use and benefits of insulin protocols within these units have 
not yet been addressed in the literature. The management of tight glycaemic control still remains under 
the influence of ineffective standards characterized by tolerance for hyperglycaemia and a reluctance to 
use insulin intensively. 
A validated Glargine and intravenous insulin-glucose pharmacodynamic model are presented. Virtual 
trial results on 16 stable ICU patients showed that Glargine can provide effective blood glucose 
management for these long term recovering patients. An initial intravenous injection and higher Glargine 
dosing is required for the first day to quickly lower elevated blood glucose levels. However, once 
patient’s blood glucose levels are within a desirable range, Glargine alone can provide effective 
glycaemic management, thus reducing nursing effort. Median blood glucose for the entire cohort when 
simulated with the combination of Glargine and an intravenous insulin injection is 6.5 with interquartile 
range of [5.6, 7.5]. The 90% confidence interval is [4.6, 9.7] with no occurrence of hypoglycaemia. This 
in silico study provides a first virtual trial analysis of the in-hospital transition between intravenous and 
subcutaneous insulin for TGC. 
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                                1. INTRODUCTION 
Stress-induced hyperglycaemia is prevalent in critical care 
and can occur in patients with no history of diabetes (Capes 
et al. 2000, Mizock et al. 2001, Van den Berghe et al. 2001). 
Critically ill patients exhibit increased endogenous glucose 
production, antogonised and erratic insulin production, and 
significantly increased insulin resistance. Hyperglycaemia 
worsens outcomes, increasing the risk of severe infection 
(Bistrian et al. 2001), myocardial infarction (McCowen et al. 
2000) and critical illnesses such as polyneuropathy and 
multiple organ failure.  
A number of studies have investigated the effects on patient 
outcomes when blood glucose levels are controlled with 
insulin, and revealed markedly positive results. The most 
notable is a study by Van den Berghe et al. (2001) who 
showed that tight glucose control averaging 6.1mmol/L 
reduced cardiac intensive care unit (ICU) patient mortality by 
18-45%. The use of IV insulin therapy in ICU patients to 
correct hyperglycaemia, whether or not a patient is a 
diagnosed diabetic, became the focus of much discussion 
following this landmark study. Krinsley et al. (2004) showed 
a 17-29% reduction in mortality over a wider ICU population 
with a higher glucose average of 7.75mmol/L. Finally, the 
SPRINT protocol reduced mortality 36-47% with a more 
critically ill cohort (Chase et al. 2008). 
While many ICU patients are benefiting from this research, 
moderate to high levels of hyperglycaemia are still tolerated 
within high dependency (HDU) and post-surgical units, such 
as the cardiac-thoracic care unit (CTCU). The use and 
benefits of insulin protocols within these units have not yet 
been widely addressed in the literature. (Whitehorn et al. 
2006). The management of tight glycaemic control in these 
units remains under the influence of ineffective standard 
characterized by a tolerance for hyperglycaemia and a  
reluctance to use insulin intensively. 
Based on current evidence from critically ill and surgical 
patients, it is logical to expect that maintenance of 
normoglycaemia within HDU patients would limit potential 
complications associated with elevated blood glucose levels. 
This assumption is not unreasonable as patients in the ICU 
and within HDU share an accelerated catabolic, 
hyperglycaemic state that also reduces the immune response. 
Extending tight control to these wards could minimise 
rebound hyperglycaemia on discharge to the wards (Goldberg 
et al. 2004) and minimise the development of (new) 
infections, thus improving overall patient care (Gubern et al. 
2006).  
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HDU patients share more similarity in metabolic status to 
patients recovering from critical illness than to critical care 
patients in general. In Chase et al. (2008), as critically ill 
patients recover, their insulin sensitivity rises, but is still low 
compared to ambulatory Type 2 diabetic individuals 
(T2DM). Consequently, their insulin requirement decreases 
and the hourly doses are generally more consistent. In this 
study, insulin Glargine is investigated to see if it can 
effectively substitute intravenous insulin for these stable long 
term critically ill patients. Glargine is a long acting insulin, 
mostly used for basal insulin support in Type 1 diabetic 
patients. It is usually only used once to twice a day. If 
Glargine can be used effectively for stable ICU and HDU 
patients, nursing workload could significantly be decreased, 
which has added benefits. (Chase et al. 2008) 
In this paper, a retrospective cohort of recovering, stable 
patients were selected from the SPRINT cohort (Chase et al. 
2008). The effect of Glargine was simulated on these patients 
in virtual trials (Chase et al. 2007) to evaluate if Glargine can 
successfully substitute insulin boluses used in the SPRINT 
protocol for these patients. This paper uses an integrated 
pharmacodynamic model of insulin Glargine, intravenous 
insulin and glucose developed from Wong et al. (2008a,b,c,d) 
and Chase et al. (2005).   
                              2.  SYSTEM MODEL 
The pharmacodymanic model used in this study integrates the 
Glargine compartmental model from Wong et al. (2008c,d) 
and the generic insulin-glucose model from Chase et al. 
(2005). The Glargine model has been validated against 
literature results (Wong et al. 2008c,d) and the model from et 
al. Chase (2005) has been clinically validated in TGC trials. 
The integrated model used in this study is defined: 
Glargine Compartmental Model: 
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where all variables in Equations (1)-(4) are defined: 
xh,gla (t) Mass in glargine hexameric compt. [mU] 
pgla(t) Mass in glargine precipitate compt. [mU] 
xdm(t) Mass in dimer/monomer compartment [mU] 
xi(t) Mass in the interstitium compartment [mU] 
rdis,max Max glargine precip. dissolution rate [mU/min] 
utotal,gla(t) Insulin glargine input [mU/min] 
up,gla(t) Glargine precip. state insulin input [mU/min] 
uh,gla(t) Glargine hexamer state insulin input [mU/min] 
um,gla(t) Glargine dimer/monomer state insulin input  
kprep,gla Glargine precipitate dissolution rate [min-1] 
k1 Hexamer dissociation rate [min-1] 
k1,gla  Glargine hexamer dissociation rate [min-1] 
k2 Dimeric/monomeric insulin transport rate into        
 interstitium [min-1] 
k3 Interstitium transport rate into plasma [min-1] 
kd i Rate of loss from interstitium [min-1] 
kd Rate of diffusive loss from hexameric and 
dimeric/monomeric state compartments [min-1] 
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where all variables in Equations (5)-(10) are defined: 
G Total plasma glucose [mmol/L] 
I Plasma insulin [mmol/L] 
Q Interstitial insulin [mU/L] 
EGP Endogenous glucose production [mmol/min] 
pG Glucose clearance [1/min] 
CNS Central nervous system uptake [mmol/min] 
SI Insulin sensitivity [L/(mU.min)], 
uex Exogenous insulin input [mU/min] 
D Enteral dextrose infusion 
P1 Represents stomach [mmol/min] 
P2 Represents gut [mmol/min] 
P Glucose appearance [mmol/min] 
n Decay rate of insulin from plasma [1/min] 
k Effective life of insulin in the system 
d1, d2 Transport rate [1/min] 
mb Body Mass [kg] 
αG Saturation of insulin-dependent glucose 
clearance [L/mU] 
αI Saturation of plasma insulin disappearance 
[L/mU] 
VG Glucose distribution volume [L] 
VI Insulin distribution volume [L] 
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Figure 1 shows the Glargine compartment model structure by 
compartments. It is taken from Wong et al (2008c).  
   
 
Figure 1. Structure of Glargine absorption kinetics model, 
starting from precipitate component pgla it flows into 
dimeric/monomeric state xdm, interstitium xi and finally to 
plasma I compartment. 
                                     3.  METHOD 
3.1 Virtual Trial Patient cohort 
The 16 patient cohorts used to create the virtual cohort for 
simulation covers a more stable portion of the general ICU 
population. These patient data are a small subset of the 
SPRINT (Chase et al. 2008) cohort. Patients were considered 
stable based on measurement frequency of 2 hours with no 
significant change in intervention or glucose, and thus cover 
only the latter portions of some patient stays. These patients 
are considered to represent a more stable patient group ready 
for transition to a less acute ward and subcutaneous insulin.  
The APACHE II score (Median: 19, Range: 11-32), age, sex 
and mortality for the cohort are shown in Table 1. The 
average length of is 4.3 days (Range: 1.9-11.7 days). It is 
worth noting that the APACHE II scores have a much higher 
median and range than the larger cohorts in the glycaemic 
control research of Van den Berghe et al. (2001), Krinsley et 
al. (2004), but is more similar to Van den Berghe et al’s more 
recent study (2006).  
3.2 Virtual Trial Simulations 
The patients time-varying insulin sensitivity (SI) was fitted to 
the actual clinical data using an integral fitting method (Hann 
et al. 2005). Constraints are placed on SI to ensure it is within 
a physiologically valid range. The resulting time-varying SI 
profiles represent time-varying metabolic status for 
individual patients. Testing new interventions with this 
profile, in simulation, provides new outputs. Thus, the profile 
of SI can be used to create “virtual patients” for testing insulin 
protocols. Using the known interventions tests the models 
prediction capability for model validation. In prior virtual 
trials, the results matched the clinical responses obtained 
when tested in the ICU (Lin et al. 2007, Chase et al. 2007 ).  
Table 1. Long-term virtual trial patient cohort 
Patient 
no. 
Medical Group APACHE II score Age Sex Mortality 
5004 Burns  11 43 F N 
5008 Resp. Failure  23 44 F 
 
N 
5020 Pancreatitis  19 68 M 
 
N 
5023 Unknown  NA 75 M 
 
N 
5028 Resp. Failure  15 67 M 
 
N 
5032 Pneumonia  31 70 M 
 
N 
5034 Pancreatitis  20 68 M 
 
N 
5050 Trauma  15 20 M 
 
N 
5058 Resp. Failure  18 75 M 
 
N 
5063 Pancreatitis  15 80 M 
 
N 
5070 Dissecting Aorta  20 76 F 
 
N 
5079 Unknown  NA 50 F 
 
N 
5092 Unknown  NA 76 M 
 
N 
5102 Sepsis  17 49 M 
 
N 
5111 Cardio. shock  29 58 M 
 
N 
5118 Haemorrhage  19 50 F 
 
N 
Median 
 (range) 
19 
 (11-31) 
57 
(20-80)   
 
In this study, the effect of Glargine was first tested where the 
sum of the clinical daily boluses for a patient is substituted by 
a single dose of Glargine. Further simulation was then carried 
out to test the effect of combining intravenous insulin 
injections with Glargine to aid the transition to subcutaneous 
insulin without losing glycaemic control. Virtual trial results 
were compared to the clinical SPRINT results to evaluate the 
performance of Glargine in place of intravenous insulin. 
                                       4.  RESULTS 
Simulation results from one patient are shown in Figure 2. 
The top panel shows the blood glucose through time. With 
Glargine only, blood glucose level for the first 50 hours is not 
well managed. This result occurs because the effective insulin 
takes a long time to build up to the same level achieved by 
using intravenous injections, as shown in the bottom panel. 
The middle panel shows the administration of insulin.  
The simulated Glargine and intravenous insulin case uses a 
“priming” insulin injection in the beginning along with 5 
times the specified insulin bolus of Glargine. This approach 
quickly builds up the effective insulin to a similar level as 
that achieved with intravenous insulin boluses only. The 
consequent blood glucose levels are similar to that achieved 
clinically, using intravenous insulin injections only. After the 
first day, the insulin requirement in Glargine is equivalent to 
that in intravenous insulin injections and is thus much lower. 
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Figure 2. Simulation results from Patient 5008. 
Figure 3 shows the responses of simulated Glargine with and 
without several different intravenous insulin boluses to raise 
the concentration of the effective interstitial insulin, Q. This 
analysis validated the choice of priming where it can be 
clearly observed how effective interstitial, Q has a different 
magnitude of build up depending on number of boluses and 
basal support. 
The cohort blood glucose results are summarised in Table 2, 
showing the blood glucose levels achieved on day 1, the rest 
of the stay and whole stay. Over the entire cohort, the highest 
median value of the glucose concentration for all three 
categories occurred on the first day. On the first day, the 
blood glucose levels achieved using Glargine only is a lot 
higher than the clinical data, and also higher than if 
intravenous insulin is incorporated. This result is also 
observed in Figure 1. For the rest of the stay, the Glargine 
only protocol is still disadvantaged compared to the other 
protocols. The protocol utilising a “priming” intravenous 
insulin injection and more Glargine on the first day achieved 
very similar results to the clinical data. None of the protocols 
resulted in hypoglycaemic events.  
 
Figure 3. Effect of Glargine and priming bolus dosing on the 
effective interstitial insulin concentration Q(t), which 
determines the final glucose lowering effect observed. The 
goal is to match the IV insulin only line for equal control. 
            Table 2.  Cohort results (all patient hours) 
 Median [IQR] 90%CI* #Hypo<2.2 
Day 1 
G^ 9.7 [9.0, 10.9] [7.6,12.7] 0 
G+IV# 6.8 [6.1, 7.9] [4.8,10.2] 0 
Clinical~ 6.2 [5.5, 7.3] [4.4,9.6] 0 
Rest of Stay 
G^ 7.5[ 6.4, 8.9] [5.1,10.6] 0 
G+IV# 6.3 [5.5, 7.3] [ 4.5, 9.7] 0 
Clinical~ 5.9[5.3,6.8] [4.6,8.6] 0 
Whole Stay 
G^ 8.0 [6.7, 9.4] [ 5.2,11.5] 0 
G+IV# 6.5[5.6,7.5] [ 4.6,9.7] 0 
Clinical~ 6.0 [5.3, 6.8] [ 4.6,9.0] 0 
*
 CI = confidence interval, ^ G = Glargine only, # G+IV = Glargine and 
intravenous insulin, ~ Clinical = Clinical SPRINT data (Chase et al, 2008) 
Figures 4-6 summarise the glycaemic control obtained as 
cumulative distribution functions for the median, 5th and 95th 
percentile patients across the cohort. They clearly show the 
differences in the tightness and variability of the glycaemic 
control resulting from the different protocols. Overall, the 
switch to subcutaneous insulin from intravenous insulin 
dosing results in some loss of control despite the relatively 
more stable cohort used. However, relatively similar control 
is obtained for Glargine using the priming intravenous insulin 
compared to the original SPRINT clinical data, which is the 
primary goal in this study. Glargine alone shows a significant 
loss of control for the median and 90%CI patient results due 
to the lower effective insulin levels it achieves initially, as 
seen in Figure 3. 
 
Figure 4. Clinical (SPRINT) per-patient blood glucose 
cumulative distribution function (CDF). Dashed box shows 
4-7 mmol/L band. The median patient has 85% of 
measurements below 7 mmol/L in this case. The 95th 
percentile patient has only ~50% below this value, and the 5th 
percentile patient has almost 100% of blood glucose values 
below 7 mmol/L. Overall, the per-patient CDFs indicate the 
tightness across patients in the cohort. 
52
  
     
 
 
Figure 5. Glargine and intravenous IV per-patient blood 
glucose CDF. Dashed box shows 4-7 mmol/L band. 
 
Figure 6. Glargine only per-patient glucose CDF. Dashed box 
shows 4-7 mmol/L band. 
5. DISCUSSION 
The efficacy of subcutaneously injected Glargine as basal 
insulin support is demonstrated in this study. Glargine is a 
slow, long acting insulin that goes through 4 compartments 
before reaching plasma. Therefore, its effect in the interstitial 
compartment builds up very slowly compared to intravenous 
insulin. It is an effective basal support for Type 1 diabetic 
patients on a daily basis. However, for a hyperglycaemic 
patient in the ICU or HDU, using Glargine alone cannot 
quickly reduce significantly elevated glycaemic levels, and a 
priming dose approach is required. 
The SPRINT protocol utilises intravenous insulin injections 
on an hourly basis to manage glycaemic levels for critically 
ill patients. Many critically ill patients have volatility 
requirements from hour to hour. This is a result of their 
critical illness and the medical interventions and drug 
therapies they receive (Chase et al., 2008). Therefore, 
intravenous insulin injections suit this situation well because 
the response is fast and does not linger when patient 
metabolic status changes. Most importantly, if a patient is 
being weaned from inotropes or other medications that 
suppress insulin sensitivity, any lingering effect of insulin is 
undesirable because insulin sensitivity may quickly recover 
and result in hypoglycaemia. 
For the patients studied in this paper, their insulin 
requirement is generally very stable and consistent from one 
hour to the next. These patients’s insulin requirements can be 
substituted by Glargine successfully, as they need only a 
constant and stable supply of effective insulin in the 
interstitial compartment. However, by using Glargine only, 
the effective insulin in the interstitial compartment does not 
build up quickly to address the initially elevated blood 
glucose levels. Therefore it was found that using twice the 
insulin bolus size specified by the SPRINT protocol as a 
“priming” intravenous insulin bolus, together with 5 times 
the required intravenous insulin as Glargine, a similar profile 
of effective interstitial insulin can be achieved to that of 
SPRINT clinical data on the first day. After this priming first 
day, a daily subcutaneous Galrgine injection of the equivalent 
amount of required intravenous insulin can be used to 
maintain the blood glucose levels in the desirable range 
effectively. 
According to Gerich et al (2006), it has been difficult for 
patients and physicians to sufficiently titrate basal insulin 
therapy for the fear of hypoglycaemia associated with (NPH) 
or Ultralente. Glargine however enables attainment of near 
normoglycaemia with lesser risk. This study successfully 
demonstrated a safe approach to use Glargine with regard to 
hypoglycaemia in these units. In general, the use of Glargine 
results in blood glucose levels slightly on the higher side 
compared to using intravenous insulin injections only. This 
result thus provides a safe and conservative alternative to 
glycaemic management in the ICU and HDU which is less 
labour intensive.  
Before this work can be extended to clinical studies in the  
HDU, several issues still need to be addressed. HDU patients 
often have meals rather than a constant naso-gastric feed used 
in the ICU. It is known for healthy individuals, endogenous 
insulin is secreted upon consumptions of food (Woods et al. 
1998). However it is not known to what degree HDU patients 
are able to support their own prandial insulin requirement. In 
addition, the variability in patient endogenous insulin 
responses will need to be addressed. Endogenous glucose 
production for HDU patients may be different from ICU 
patients as well. All these issues should ideally be 
investigated through clinical data gathering.  
                                     6. CONCLUSIONS 
This paper presented a validated Glargine and intravenous 
insulin-glucose pharmacodynamic model. The in-silico 
virtual trial results for 16 stable ICU patients showed that 
Glargine can provide effective blood glucose management for 
these patients. An initial intravenous injection and higher 
Glargine dosing is required for the first day to quickly lower 
elevated blood glucose level. Once the patient’s blood 
glucose levels are within a desirable range, Glargine alone 
can provide effective glycaemic management, reducing 
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nursing effort. The overall results show one approach to 
managing the intravenous to subcutaneous insulin transition 
that occurs as patients leave intensive care for less acute 
wards during their hospital stay. Safe, effective approaches to 
this transition will ensure that clinical burden and workload 
are not increased, while maintaining the benefits of tight 
glycemic control. 
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